Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer

British Journal of Cancer

Volumn 94, Issue 9, 2006, Pages 1293-1299

  Graeven, U ^a   Kremer, B ^b   Sudhoff Th ^a   Killing, B ^a   Rojo, F ^c   Weber, D ^d   Tillner, J ^d   Unal C ^e   Schmiegel, W ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d MERCK KGAA   (Germany)

^e EMD Pharmaceuticals   (United States)

Author keywords

EMD 72000; Epidermal growth factor receptor; Gemcitabine; Matuzumab; Pancreatic cancer

Indexed keywords

EMD 7200; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; MATUZUMAB;

ADULT; ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLICULITIS; HEADACHE; HUMAN; HYPOTENSION; LEUKOPENIA; LIFE EXPECTANCY; MALE; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN BIOPSY; SKIN DISEASE; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 33646504884     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603083     Document Type: Article

References (24)

1. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Rosello J, Nicholson RI, Mendelsohn J, Baselga J (2001) Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61: 6500-6510
2. Amendt C, Mantell O, Peters M, Yezhelyev M, Jauch K, Geissler E, Bruns C (2003) In vivo activity of humanized monoclonal anti-EGFR antibody EMD72000 in combination with gemcitabine on growth of primary pancreatic tumors and metastases in an orthotopic nude mouse model [abstract]. Proc Am Assoc Cancer Res 44(2nd ed): 1234
3. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302
4. Burger AM, Heiss NS, Kreysch HG, Schandelmaier K, Wirth G, Fiebig FH, Grell M (2003) The humanized monoclonal anti-EGFR antibody EMD72000 potently inhibits the growth of EGFR-expressing human tumor xenografts insensitive to chemotherapeutic drugs [abstract]. Proc Am Assoc Cancer Res 44(2nd ed): 1139
5. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413
6. Graeven U, Vogel I, Killing B, Hinz S, Von Bernstorff W, Baselga J, Rojo F, Tillner J, Gropp P, Schmiegel W (2004) Phase I study of humanized IgG1anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD 72000 plus gemcitabine (Gem) in advanced pancreatic cancer [abstract]. J Clin Oncol 22(14S): 210s
7. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267-3279
8. Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM (1991) Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng 4: 773-783
9. Kollmannsberger C, Schittenhelm M, Honecker F, Rosen O, Tillner J, Kanz L, Bokemeyer C (2003) Epidermal growth factor receptor (EGFR) antibody EMD 72000 in combination with paclitaxel (P) in patients (pts) with EGFR-positive advanced non-small cell lung cancer (NSCLC): a phase I study [abstract]. Proc Am Soc Clin Oncol 22: 627
10. Lemoine NR, Hughes CM, Barton CM, Poulsom R, Jeffery RE, Kloppel G, Hall PA, Gullick WJ (1992) The epidermal growth factor receptor in human pancreatic cancer. J Pathol 166: 7-12
11. Lo KM, Lan Y, Zhang X, Gillies SD (2003) The role of ADCC effector function in the anti-tumor activity of anti-EGFR antibodies in a mouse xenograft model [abstract]. Clin Cancer Res 9: A123
12. Needle MN (2002) Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Semin Oncol 29: 55-60
13. Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49: 33-64
14. Salazar R, Tabernero J, Rojo F, Jimenez E, Montaner I, Casado E, Sala G, Tillner J, Malik R, Baselga J (2004) Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w). A phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD) [abstract]. J Clin Oncol 22(14S): 127s
15. Schmiegel W, Schmielau J, Henne-Bruns D, Juhl H, Roeder C, Buggisch P, Onur A, Kremer B, Kalthoff H, Jensen EV (1997) Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer. Proc Natl Acad Sci USA 94: 12622-12626
16. Schwartz G, Dutcher JP, Vogelzang NJ, Gollob J, Thompson J, Bukowski RM, Figlin RA, Lohner M, Roskos L, Hwang CC, Foon KA, Schwab G, Rowinsky EK (2002) Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer [abstract]. Proc Am Soc Clin Oncol 21: 24
17. Tabernero J, Rojo F, Jimenez E, Montaner I, Santome L, Guix M, Rosen O, Kovar A, Salazar R, Baselga J (2003) A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-h (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth. Proc Am Soc Clin Oncol 22: 192 (abstr. 770)
18. Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM (2004) Evaluation of biological endpoints and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22: 3080-3090
19. Thomas SM, Grandis JR (2004) Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 30: 255-268
20. Tillner J, Golob M, Vanhoefer U, Tabernero J, Rosen O, Kovar A (2003) Pharmacokinetics (PK) of the novel humanized anti-EGFR MAb EMD 72000 [abstract]. Clin Cancer Res 9: 77
21. Tobita K, Kijima H, Dowaki S, Kashiwagi H, Ohtani Y, Oida Y, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, Inokuchi S, Makuuchi H (2003) Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 11: 305-309
22. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A, Baselga J (2004) Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22: 175-184
23. Xiong HQ, Abbruzzese JL (2002) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29: 31-37
24. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22: 2610-2616